JP2014530246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530246A5 JP2014530246A5 JP2014536225A JP2014536225A JP2014530246A5 JP 2014530246 A5 JP2014530246 A5 JP 2014530246A5 JP 2014536225 A JP2014536225 A JP 2014536225A JP 2014536225 A JP2014536225 A JP 2014536225A JP 2014530246 A5 JP2014530246 A5 JP 2014530246A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- sulfated glycosaminoglycan
- administered
- dose
- sulfated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548606P | 2011-10-18 | 2011-10-18 | |
| EP11185648.0 | 2011-10-18 | ||
| EP11185648 | 2011-10-18 | ||
| US61/548,606 | 2011-10-18 | ||
| PCT/EP2012/070615 WO2013057167A1 (en) | 2011-10-18 | 2012-10-18 | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530246A JP2014530246A (ja) | 2014-11-17 |
| JP2014530246A5 true JP2014530246A5 (https=) | 2015-11-26 |
| JP6072810B2 JP6072810B2 (ja) | 2017-02-01 |
Family
ID=48140372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536225A Expired - Fee Related JP6072810B2 (ja) | 2011-10-18 | 2012-10-18 | 第ｖｉｉｉ因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9393289B2 (https=) |
| EP (1) | EP2768522B1 (https=) |
| JP (1) | JP6072810B2 (https=) |
| KR (1) | KR20140083036A (https=) |
| CN (1) | CN103889445A (https=) |
| AU (1) | AU2012318279B2 (https=) |
| CA (1) | CA2852397A1 (https=) |
| DK (1) | DK2768522T3 (https=) |
| ES (1) | ES2600081T3 (https=) |
| WO (1) | WO2013057167A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2851057A1 (en) | 2011-10-18 | 2013-04-25 | Csl Behring Gmbh | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii |
| EP3152230B1 (en) | 2014-06-06 | 2019-08-07 | Octapharma AG | Preparation comprising factor viii and von willebrand factor peptides |
| CN107135654B (zh) * | 2014-09-12 | 2021-10-29 | 加利福尼亚大学董事会 | 巨胞饮人类抗cd46抗体和靶向癌症疗法 |
| KR102554850B1 (ko) * | 2015-02-06 | 2023-07-13 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 |
| SE539575C2 (en) * | 2015-07-30 | 2017-10-17 | Tx Medic Ab | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| ATE72838T1 (de) | 1985-04-12 | 1992-03-15 | Genetics Inst | Neue prokoagulierungsproteine. |
| FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A0 (en) * | 1994-03-31 | 1995-10-31 | Pharmacia Ab | Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| PT1754718E (pt) | 1996-04-24 | 2011-07-13 | Univ Michigan | Factor viii resistente à inactivação |
| AU1598200A (en) | 1998-10-23 | 2000-05-15 | Trustees Of The University Of Pennsylvania, The | Systemic delivery of gene products via skin |
| CA2450125A1 (en) | 2001-06-15 | 2002-12-27 | Andre C. Schuh | Gene therapy for hemophilia a |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| PT1624891E (pt) | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
| CA2704234A1 (en) * | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| KR101582841B1 (ko) | 2008-02-27 | 2016-01-11 | 노보 노르디스크 에이/에스 | 콘쥬게이트된 인자 ｖｉｉｉ 분자 |
| KR20120061898A (ko) | 2009-08-20 | 2012-06-13 | 체에스엘 베링 게엠베하 | 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자 |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
-
2012
- 2012-10-18 CN CN201280051236.7A patent/CN103889445A/zh active Pending
- 2012-10-18 WO PCT/EP2012/070615 patent/WO2013057167A1/en not_active Ceased
- 2012-10-18 DK DK12777895.9T patent/DK2768522T3/en active
- 2012-10-18 JP JP2014536225A patent/JP6072810B2/ja not_active Expired - Fee Related
- 2012-10-18 US US14/352,540 patent/US9393289B2/en not_active Expired - Fee Related
- 2012-10-18 CA CA2852397A patent/CA2852397A1/en not_active Abandoned
- 2012-10-18 AU AU2012318279A patent/AU2012318279B2/en not_active Ceased
- 2012-10-18 EP EP12777895.9A patent/EP2768522B1/en not_active Not-in-force
- 2012-10-18 KR KR1020147013300A patent/KR20140083036A/ko not_active Withdrawn
- 2012-10-18 ES ES12777895.9T patent/ES2600081T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021050953A8 (en) | Compositions and methods for the delivery of therapeutic biologics for treatment of disease | |
| JP2016517421A5 (https=) | ||
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| JP2012041342A5 (https=) | ||
| MX2022007012A (es) | Uso de un agonista doble del receptor de glp-1/glucagon de larga accion para el tratamiento de la enfermedad de higado graso no alcoholico. | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| WO2012012347A3 (en) | Methods of intravenous administration of glyburide and other drugs | |
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| JP2016508123A5 (https=) | ||
| JP2014530873A5 (https=) | ||
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| JP2014530246A5 (https=) | ||
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| MX2009010268A (es) | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| JP2013520447A5 (https=) | ||
| FI3590960T3 (fi) | Perifeeristen hermojen IgG-stimuloitu remyelinaatio | |
| WO2019094823A3 (en) | Mitochondrial localization signals in human tafazzin and uses thereof | |
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| WO2014145199A3 (en) | Retrograde delivery of sdf-1 for treatment of myocardial infarction |